MTAP and myxofibrosarcoma: By integrating various methodologies, we identified the clinical, biological, and therapeutic relevance of MTAP deficiency, which was observed in 37% of primary myxofibrosarcomas, strongly linked to homozygous deletion or promoter methylation, and independently predictive of adverse survival.